Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 130-136 , August 2009

Cancer Immunotherapy

  • Philip J. Bergman, DVM, MS, PhD, DACVIM-Oncology

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: Philip J. Bergman, DVM, MS, PhD, Dipl. ACVIM-Oncology, 80 Business Park Dr, Ste 110, Armonk, NY 10504

References 

  1. Bergman PJ. Biologic response modification. In:  Rosenthal RC editors. Veterinary Oncology Secrets. ed 1. Philadelphia: Hanley & Belfus, Inc; 2001;p. 79–82
  2. Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer?. Curr Opin Investig Drugs. 2001;2(1):133–135
  3. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2(4):293–299
  4. Wallace ME, Smyth MJ. The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity. Springer Semin Immunopathol. 2005;27(1):49–64
  5. Catchpole B, Gould SM, Kellett-Gregory LM, Dobson JM. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma. J Small Anim Pract. 2002;43(10):464–467
  6. Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov Today. 2004;9(2):72–81
  7. Morse MA, Mosca PJ, Clay TM, Lyerly HK. Dendritic cell maturation in active immunotherapy strategies. Expert Opin Biol Ther. 2002;2(1):35–43
  8. Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 2006;16(2):115–123
  9. Richardson MA, Ramirez T, Russell NC, Moye LA. Coley toxins immunotherapy: a retrospective review. Altern Ther Health Med. 1999;5(3):42–47
  10. Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol. 2008;179:53–56
  11. Owen LN, Bostock DE. Proceedings: Tumour therapy in dogs using B.C.G. Br J Cancer. 1974;29:95
  12. MacEwen EG. An immunologic approach to the treatment of cancer. Vet Clin North Am. 1977;7:65–75
  13. Theilen GH, Hills D. Comparative aspects of cancer immunotherapy: immunologic methods used for treatment of spontaneous cancer in animals. J Am Vet Med Assoc. 1982;181:1134–1141
  14. MacEwen EG. Approaches to cancer therapy using biological response modifiers. Vet Clin North Am Small Anim Pract. 1985;15:667–688
  15. Klein WR, Rutten VP, Steerenberg PA, Ruitenberg EJ. The present status of BCG treatment in the veterinary practice. In Vivo. 1991;5:605–608
  16. Henry CJ, Downing S, Rosenthal RC, et al. Evaluation of a novel immunomodulator composed of human chorionic gonadotropin and bacillus Calmette-Guerin for treatment of canine mast cell tumors in clinically affected dogs. Am J Vet Res. 2007;68:1246–1251
  17. Parodi AL, Misdorp W, Mialot JP, et al. Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother. 1983;15:172–177
  18. MacEwen EG, Patnaik AK, Harvey HJ, Hayes AA, Matus R. Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum. Cancer Invest. 1986;4(5):397–402
  19. Thamm DH, Kurzman ID, King I, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 2005;11:4827–4834
  20. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998;101:2406–2414
  21. Kleinerman ES, Jia S-F, Griffin J, Seibel NL, Benjamin RS, Jaffe N. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration. J Clin Oncol. 1992;10:1310–1316
  22. MacEwen EG, Kurzman ID, Vail DM, et al. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999;5:4249–4258
  23. Teske E, Rutteman GR, vd Ingh TS, van NR, Misdorp W. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE): a randomized clinical trial in dogs with mammary carcinoma. Anticancer Res. 1998;18:1015–1019
  24. Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res. 1995;1:1595–1601
  25. Vail DM, MacEwen EG, Kurzman ID, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res. 1995;1:1165–1170
  26. Smith BF, Curiel DT, Ternovoi VV, et al. Administration of a conditionally replicative oncolytic canine adenovirus in normal dogs. Cancer Biother Radiopharm. 2006;21:601–606
  27. Le LP, Rivera AA, Glasgow JN, et al. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 2006;13:389–399
  28. Hemminki A, Kanerva A, Kremer EJ, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther. 2003;7:163–173
  29. Suter SE, Chein MB, von Messling V, et al. In vitro canine distemper virus infection of canine lymphoid cells: a prelude to oncolytic therapy for lymphoma. Clin Cancer Res. 2005;11:1579–1587
  30. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs. 2008;17:1051–1065
  31. Gill VL, Bergman PJ, Baer KE, Craft D, Leung C. Use of imiquimod 5% cream (Aldara™) in cats with multicentric squamous cell carcinoma in situ: 12 cases (2002-2005). Vet Comp Oncol. 2008;6:55–64
  32. Peters-Kennedy J, Scott DW, Miller WH. Apparent clinical resolution of pinnal actinic keratoses and squamous cell carcinoma in a cat using topical imiquimod 5% cream. J Feline Med Surg. 2008;10:593–599
  33. Tateyama S, Priosoeryanto BP, Yamaguchi R, Uchida K, Ogiwara K, Suchiya AT. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumors. Res Vet Sci. 1995;59:275–277
  34. Kruth SA. Biological response modifiers: interferons, interleukins, recombinant products, liposomal products. Vet Clin North Am Small Anim Pract. 1998;28:269–295
  35. Whitley EM, Bird AC, Zucker KE, Wolfe LG. Modulation by canine interferon-gamma of major histocompatibility complex and tumor-associated antigen expression in canine mammary tumor and melanoma cell lines. Anticancer Res. 1995;15:923–929
  36. Hampel V, Schwarz B, Kempf C, et al. Adjuvant immunotherapy of feline fibrosarcoma with recombinant feline interferon-omega. J Vet Intern Med. 2007;21:1340–1346
  37. Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther. 2008;15:267–276
  38. Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S. Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol. 2008;423:319–325
  39. Finocchiaro LM, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma. Cancer Gene Ther. 2008;15:165–172
  40. Akhtar N, Padilla ML, Dickerson EB, et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia. 2004;6:106–116
  41. Dickerson EB, Fosmire S, Padilla ML, Modiano JF, Helfand SC. Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer. J Immunother. 2002;25:36–45
  42. Okano F, Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res. 2000;20:3411–3415
  43. Jahnke A, Hirschberger J, Fischer C, et al. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med. 2007;54:599–606
  44. Dickerson EB, Akhtar N, Steinberg H, et al. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res. 2004;2:663–673
  45. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther. 2005;16:937–946
  46. Skubitz KM, Anderson PM. Inhalational interleukin-2 liposomes for pulmonary metastases: a phase I clinical trial. Anticancer Drugs. 2000;11:555–563
  47. Khanna C, Anderson PM, Hasz DE, Katsanis E, Neville M, Klausner JS. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer. 1997;79:1409–1421
  48. Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies. Clin Cancer Res. 1996;2:721–734
  49. Jourdier TM, Moste C, Bonnet MC, et al. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther. 2003;10(26):2126–2132
  50. Siddiqui F, Li CY, Zhang X, et al. Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy. Int J Hyperthermia. 2006;22:117–134
  51. Quintin-Colonna F, Devauchelle P, Fradelizi D, et al. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 1996;3(12):1104–1112
  52. Kamstock D, Guth A, Elmslie R, et al. Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther. 2006;13:306–317
  53. Junco JA, Basalto R, Fuentes F, et al. Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med Biol. 2008;617:581–587
  54. Chou PC, Chuang TF, Jan TR, et al. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles. Vet Immunol Immunopathol. 2009;130:25–34
  55. Chuang TF, Lee SC, Liao KW, et al. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer. 2009;125:698–707
  56. Bergman PJ. Anticancer vaccines. Vet Clin North Am Small Anim Pract. 2007;37:1111–1119
  57. Hogge GS, Burkholder JK, Culp J, et al. Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. Cancer Gene Ther. 1999;6(1):26–36
  58. Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother. 2006;55(4):433–442
  59. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med. 2007;21:113–120
  60. Bird RC, Deinnocentes P, Lenz S, Thacker EE, Curiel DT, Smith BF. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol. 2008;123:289–304
  61. Turek MM, Thamm DH, Mitzey A, et al. Human granulocyte and macrophage colony-stimulating factor DNA cationic-lipid complexed autologous tumour cell vaccination in the treatment of canine B-cell multicentric lymphoma. Vet Comp Oncol. 2007;5:219–231
  62. Kuntsi-Vaattovaara H, Verstraete FJM, Newsome JT, Yuan H. Resolution of persistent oral papillomatosis in a dog after treatment with a recombinant canine oral papillomavirus vaccine. Vet Comp Oncol. 2003;1:57–63
  63. Milner RJ, Salute M, Crawford C, Abbot JR, Farese J. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine. Vet Immunol Immunopathol. 2006;114:273–284
  64. Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother. 2007;56:1299–1309
  65. von EH, Sadeghi A, Carlsson B, et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother. 2008;31:377–384
  66. Johnston KB, Monteiro JM, Schultz LD, et al. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes. Virology. 2005;336:208–218
  67. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, et al. Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen. J Vet Intern Med. 2005;19(1):56–63
  68. Tamura K, Arai H, Ueno E, et al. Comparison of dendritic cell-mediated immune responses among canine malignant cells. J Vet Med Sci. 2007;69:925–930
  69. Tamura K, Yamada M, Isotani M, et al. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. Vet J. 2008;175:126–129
  70. Rodriguez-Lecompte JC, Kruth S, Gyorffy S, Wan YH, Gauldie J. Cell-based cancer gene therapy: breaking tolerance or inducing autoimmunity?. Anim Health Res Rev. 2004;5:227–234
  71. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13:905–918
  72. Mason NJ, Coughlin CM, Overley B, et al. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma. Gene Ther. 2008;15:955–965
  73. Jeglum KA. Chemoimmunotherapy of canine lymphoma with adjuvant canine monoclonal antibody 231. Vet Clin North Am Small Anim Pract. 1996;26(1):73–85
  74. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine. 2006;24(21):4582–4585
  75. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res. 2003;9(4):1284–1290
  76. Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immunol. 2006;6:8
  77. Goubier A, Fuhrmann L, Forest L, et al. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNgamma T cell responses in the dog. Vaccine. 2008;26:2186–2190
  78. Bergman PJ, Wolchok JD. Of mice and men (and dogs): development of a xenogeneic DNA vaccine for canine oral malignant melanoma. Cancer Ther. 2008;6:817–826
  79. Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther. 2007;15:2044–2050
  80. Perales MA, Yuan J, Powel S, et al. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther. 2008;16:2022–2029
  81. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18(2):206–213
  82. Biller BJ, Elmslie RE, Burnett RC, Avery AC, Dow SW. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol. 2007;116:69–78
  83. Thamm DH. Interactions between radiation therapy and immunotherapy: the best of two worlds?. Vet Comp Oncol. 2006;4:189–197
  84. Walter CU, Biller BJ, Lana SE, Bachand AM, Dow SW. Effects of chemotherapy on immune responses in dogs with cancer. J Vet Intern Med. 2006;20(2):342–347
  85. Emens LA, Jaffee EM. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 2005;65(18):8059–8064

PII: S1938-9736(09)00047-6

doi: 10.1053/j.tcam.2009.06.001

Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 130-136 , August 2009

Article Tools